Pharmarise Holdings Corp. (2796) AI Stock Analysis

• Market Cap: ¥6.16B
• Dividend Yield: 2.61%
• Average Volume (3M): 15.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: 15.66%
• EPS Growth: 56.93%
• Country: JP
• Employees: 1,848
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -1.62
• Shares Outstanding: 12,060,381
• 10 Day Avg. Volume: 9,170
• 30 Day Avg. Volume: 15,546
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: ¥551.00 ▲(2.61% Upside)

Pharmarise Holdings Corp. receives a moderate score due to strong cash flow generation and positive technical indicators, despite challenges in profitability and valuation concerns. The absence of earnings call data and corporate events limits further insights.

Pharmarise Holdings Corp. Business Overview & Revenue Model

Company Description

Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenience stores; and sells cosmetics. In addition, it is involved in the storage and management of medical examination records of patients on behalf of medical institutions; operation of medical mall; and provision of temporary help. As of May 31, 2021, the company operated 347 stores. Pharmarise Holdings Corporation was incorporated in 1984 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Pharmarise Holdings Corp. generates revenue through multiple channels, primarily by selling its pharmaceutical products to healthcare providers, pharmacies, and hospitals. The company has a significant revenue stream from prescription medications, which includes both branded and generic drugs. Additionally, Pharmarise earns income from over-the-counter products that are marketed directly to consumers. The company also invests in research and development to create innovative therapies, which can lead to lucrative licensing agreements and partnerships with other biotech firms. Collaboration with healthcare institutions and participation in clinical trials further contribute to revenue through grant funding and shared research initiatives. Overall, Pharmarise's diverse product portfolio and strategic partnerships play a crucial role in sustaining and growing its earnings.

Pharmarise Holdings Corp. Financial Statement Overview

Summary

Pharmarise Holdings Corp. shows moderate revenue growth and strong cash flow generation. However, challenges in profitability, high leverage, and negative net income impact the financial performance score.

Income Statement

Pharmarise Holdings Corp. has shown moderate revenue growth with a 5.2% increase in the latest year. However, the company is struggling with profitability, as indicated by a negative net income and declining EBIT margins. The gross profit margin remains stable, but the net profit margin is negative, highlighting challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of approximately 2.08, indicating a relatively high leverage. The equity ratio is stable, suggesting a balanced asset structure. However, the negative return on equity indicates inefficiencies in generating returns from shareholders' investments.

Cash Flow

Cash flow analysis shows a strong free cash flow growth rate of 74.2%, indicating improved cash generation capabilities. The operating cash flow to net income ratio is positive, suggesting effective cash conversion despite negative net income. However, the free cash flow to net income ratio is below 1, indicating potential challenges in sustaining cash flow levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.37B	63.51B	54.47B	52.03B	51.61B	52.32B
Gross Profit	8.20B	8.96B	8.45B	8.13B	8.12B	8.07B
EBITDA	878.50M	1.68B	1.38B	2.33B	2.69B	2.62B
Net Income	-800.00M	-367.00M	-351.00M	333.00M	447.00M	426.00M
Balance Sheet
Total Assets	31.10B	31.92B	29.49B	23.42B	23.75B	24.72B
Cash, Cash Equivalents and Short-Term Investments	2.24B	4.92B	7.15B	4.74B	3.99B	4.60B
Total Debt	14.25B	14.28B	12.75B	9.14B	9.91B	10.70B
Total Liabilities	24.10B	25.01B	22.05B	16.43B	17.05B	18.39B
Stockholders Equity	6.95B	6.87B	7.36B	6.88B	6.61B	6.22B
Cash Flow
Free Cash Flow	349.50M	609.00M	2.10B	1.98B	247.00M	1.39B
Operating Cash Flow	427.00M	1.31B	2.71B	2.52B	713.00M	1.95B
Investing Cash Flow	-1.29B	-4.46B	-3.12B	-703.00M	-292.00M	-1.08B
Financing Cash Flow	1.95B	939.00M	2.77B	-1.07B	-1.03B	-728.00M

Pharmarise Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 537.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Positive. The current price of 537 is above the 20-day moving average (MA) of 524.80, above the 50-day MA of 514.92, and above the 200-day MA of 490.22, indicating a bullish trend. The MACD of 4.61 indicates Negative momentum. The RSI at 62.24 is Neutral, neither overbought nor oversold. The STOCH value of 96.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2796.

Pharmarise Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3417	―	¥19.36B	6.76	―	1.85%	3.70%	37.00%
4350	―	¥14.46B	11.97	―	2.40%	5.93%	-36.11%
3544	―	¥11.21B	15.39	―	1.23%	4.08%	51.63%
7679	―	¥41.28B	9.21	―	1.34%	7.12%	14.14%
2796	―	¥6.16B	―	―	2.61%	15.66%	56.93%
8095	―	¥19.49B	―	―	3.70%	15.00%	-195.87%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pharmarise Holdings Corp. Corporate Events

Pharmarise Holdings Reports Strong Q1 Financial Performance

Pharmarise Holdings Corporation reported a significant increase in its financial performance for the first three months of the fiscal year ending May 31, 2026, with net sales rising by 10% year-on-year. Despite a net loss attributable to owners of the parent, the company achieved substantial growth in operating and ordinary profit, indicating improved operational efficiency and market positioning. The company’s financial outlook for the fiscal year remains positive, with expected growth in net sales and profits, reflecting its strategic focus on enhancing shareholder value.

The most recent analyst rating on (JP:2796) stock is a Hold with a Yen520.00 price target. To see the full list of analyst forecasts on Pharmarise Holdings Corp. stock, see the JP:2796 Stock Forecast page.